Schering-Plough Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval to PEGINTRON (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for use in previously untreated patients 3 years of age and older with chronic hepatitis C.
The details can be read here.
No comments:
Post a Comment